Drug treatment and cost of cardiovascular disease in Australia

Cardiovascular Therapeutics

Volumn 27, Issue 3, 2009, Pages 164-172

  Ademi, Zanfina ^a   Liew, Danny ^b   Chew, Derek ^c   Conner, Greg ^d   Shiel, Louise ^a   Nelson, Mark ^e   Soman, Ash ^f   Steg, Gabriel ^g   Bhatt, Deepak L ^h   Reid, Christopher ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c FLINDERS MEDICAL CENTRE   (Australia)

^d LIVERPOOL HOSPITAL   (Australia)

^e UNIVERSITY OF TASMANIA   (Australia)

^f Université Paris 7 and AP HP ^*

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h MONASH UNIVERSITY   (Australia)

Author keywords

Average annual costs; Cardiovascular disease; Medicine

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; METHYLDOPA; NICOTINIC ACID; NITRATE; PRAZOSIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; AUSTRALIA; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG COST; FEMALE; GENERAL PRACTICE; GOVERNMENT; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; REIMBURSEMENT;

AGED; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; ATHEROSCLEROSIS; AUSTRALIA; BODY MASS INDEX; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; EMPLOYMENT; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; REGISTRIES; RISK FACTORS; RURAL POPULATION; SOCIOECONOMIC FACTORS; SUBURBAN POPULATION; URBAN POPULATION;

EID: 68849105936     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2009.00090.x     Document Type: Article

References (45)

1. Pharmaceutical Benefits Schedule Item Reports. Period September 2006 to September 2007. Available from : https://www.medicareaustralia.gov.au/ statistics/pbs-item.shtml.
2. Migliaccio-Walle K, Caro JJ, Ishak KJ, O'Brien JA. Costs and medical care consequences associated with the diagnosis of peripheral arterial disease. Pharmacoeconomics 2005 23 : 733 742.
3. Bruggenjurgen B, Rupprecht H, Willich S, et al. Cost of atherothrombotic diseases-myocardial infarction, ischeamic stroke and peripherial arterial occlusive disease-in Germany. J Public Health 2005 13 : 216 224.
4. Viles-Gonzalez JF, Fuster V, Badimon JJ. Atherothrombosis: A widespread disease with unpredictable and life-threatening consequences. Eur Heart J 2004 25 : 1197 207.
5. Leys D. Atherothrombosis: A major health burden. Cerebrovasc Dis 2001 11 (Suppl 2 1 4.
6. Hay J. The cost effectiveness of cardiovascular medicines. Curr Atheroscler Rep 2005 7 : 79 80.
7. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. New Engl J Med 2008 358 : 1887 1898.
8. Cathomas G, Erne P, Schwenkglenks M, Szucs TD. The economic efficiency of amlodipine in the treatment of coronary atherosclerosis - an analysis based on the PREVENT study. Cardiovasc Drugs Ther 2002 16 : 61 66.
9. Cutler DM, Long G, Berndt ER, Royer J, Fournier AA, Sasser A, Cremieux P. The value of antihypertensive drugs: A perspective on medical innovation. Health Aff 2007 26 : 97 110.
10. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001 358 : 1033 1041.
11. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003 362 : 782 788.
12. Linjer E, Hedner T, Jonsson B, et al. Cost analysis of different pharmacological treatment strategies in elderly hypertensives. Blood Press 2005 14 : 107 113.
13. Remme WJ. Secondary prevention of coronary artery disease and the choice of the ACE inhibitor why EUROPA and not PEACE. Cardiovasc Drugs Ther 2007 21 : 405 407.
14. Amarenco P, Goldstein LB, Szarek M, et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2007 38 : 3198 3204.
15. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. New Engl J Med 1999 341 : 70 76.
16. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. New Engl J Med 1996 335 : 1001 1009.
17. Heart Protection Study Collaborative Group. MRCBHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebocontrolled trial. Lancet 2002 360 : 7 22.
18. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996 348 : 1329 1339.
19. Lamotte M, Annemans L, Evers T, Kubin M. A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease. Pharmacoeconomics 2006 24 : 155 169. (Pubitemid 43242197)
20. Access Economics. The shifting burden of cardiovascular disease in Australia National Heart Foundation of Australia, 2005. Available from : http://www.heartfoundation.org.au/SiteCollectionDocuments/ cvd%20shifting%20burden.pdf
21. Nelson MR, McNeil JJ, Peeters A, Reid CM, Krum H. PBSRPBS cost implications of trends and guideline recommendations in the pharmacological management of hypertension in Australia, 1994-1998. Med J Aust 2001 174 : 565 568.
22. Ohman EM, Bhatt DL, Steg PG, et al. The Reduction of Atherothrombosis for Continued Health (REACH) Registry: An international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J 2006 151 : 786e1 e10.
23. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006 295 : 180 189.
24. Reid C, Nelson MR, Shiel L, Chew D, Connor G, DeLooze F. Australians at risk: Management of cardiovascular risk factors in the REACH Registry. Heart Lung Circ 2008 17 : 114 118.
25. Schedule of Pharmaceutical Benefits for approved pharmacists and medical practitioners 2007. Available from : http://www.pbs.gov.au/html/healthpro/ publication/view?date=20070901&type=FlashPaper&name=general-schedule
26. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand. Reducing risk in heart disease 2007 (updated 2008). Available from : http://www.heartfoundation.org.au/SiteCollectionDocuments/ A%20RR%20RRIHD%202008Update%20Guideline%20pdf.pdf.
27. Smith SC, Allen JJ, Blair SN, et al. AHAACC Guidelines for secondary prevention with coronary and other atherosclerotic vascular disease: 2006 Update: Endoresed by National Heart, Lung, and Blood Institute. Circulation 2006 113 : 2363 2372.
28. Mahoney EM, Wang K, Bruggenjurgen B, Bakhai A. Medication Use and associated annual costs in patients at risk of atherothrombosis: Results for Germany, Spain and The UK from the REACH registry. Presented at: International Society for Pharmacoeconomics and Outcomes Research Conference; 2006 Copenhagen, Denmark. 2007.
29. Yamazaki T, Goto S, Shigematsu H, et al. Prevalence, awareness and treatment of cardiovascular risk factros in patients at high risk of atherothrombosis in Japan results from domestic baseline data of the REACH registry. Circ J 2007 71 : 995 1003.
30. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996 143 : 1 13.
31. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. New Engl J Med 2005 353 : 2373 2383.
32. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. New Engl J Med 2006 354 : 1706 1717.
33. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet 2004 364 : 331 337.
34. Smith SC Jr., Allen J, Blair SN, et al. AHAACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: Endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006 113 : 2363 2372. (Pubitemid 43947981)
35. Revised PBS criteria for lipid-modifying drugs (Ocetober 2006). Available from : http://wwwnpsorgau/-data/assets/pdf-file/0020/23717/pbs-lmd-criteriapdf.
36. Begg S, Vos T, Barker B, Stevenson C, Stanley L, AD L. The burden of disease and injury in Australia 2003. PHE 82. Canberra : AIHW, 2007.
37. Hyman DJ, Pavlik VN. Self reported hypertension treatment practices among primary care physicians. Arch Intern Med 2000 : 2281 2286.
38. Berlowitz DR, Ash AS. Inadequate management of blood pressure in hypertensive population. New Engl J Med 1998 15 : 237 244.
39. Ken T. Why treatment varies so greatly. Med Econ 1997 74 : 40.
40. Garfield FB, Garfield JM. Clinical judgment and clinical practice guidelines. Int J Technol Assess Health Care 2000 16 : 1050 1060.
41. Magrini N, Einarson T, Vaccheri A, McManus P, Montanaro N, Bergman U. Use of lipid-lowering drugs from 1990 to 1994: An international comparison among Australia, Finland, Italy (Emilia Romagna Region), Norway and Sweden. Eur J Clin Pharmacol 1997 53 : 185 189.
42. Mant A, Lowinger J, Hall W, Whicker S, Ringland C, Stark H. Statins down under. BJCP 2006 63 : 125 127.
43. Stocks NP, Ryan P, McLroy H, Allan J. Statin prescribing in Australia: Socioeconomic and sex differences. A cross-sectional study. Med J Aust 2004 180 : 229 231.
44. Senes S, Penm E. Australian Institute of Health and Welfare. Medicines for cardiovascular health: Are they used appropriately Cardiovascular disease series no. 27. Cat. no. 36. Canberra : AIHW, 2007.
45. Simons LA, Ortiz M, Calcino G. Persistence with antihypertensive medication: Australia-wide experience, 2004-2006. Med J Aust 2008 188 : 224 227.